Could a simple drug boost ECT for depressed teens?

NCT ID NCT07247968

Recruiting now Symptom relief Sponsor: Min Su Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding a low dose of esketamine (a fast-acting anesthetic) to standard electroconvulsive therapy (ECT) can improve depression outcomes in adolescents aged 13-17 with severe depression. About 220 participants will be randomly assigned to receive either esketamine or a placebo alongside ECT. The main goal is to see if more teens respond to treatment in the esketamine group.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADOLESCENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Depression depressive disorder major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADOLESCENT DEPRESSION ECT ESKETAMINE

Contacts and locations

Locations

The First Affiliated Hospital of Chongqing Medical University
NOT_YET_RECRUITING

Chongqing, China
The First Affiliated Hospital of Chongqing Medical University
RECRUITING

Chongqing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.